Asha Das, M.D., has served as Tocagen’s chief medical officer since March 2017 and was previously Tocagen’s vice president, clinical development and medical affairs since April 2015. She holds more than ten years of experience in drug development, including leading activities related to the approval and launch of Avastin® in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to PD-L1. From April 2008 to April 2015, Dr. Das served in positions of increasing responsibility at Genentech Inc., a biotechnology company and member of the Roche Group, initially as associate medical director and ultimately as group medical director. From 2005 to 2008, Dr. Das served as associate medical director at Eisai Inc., a pharmaceutical company, where she focused on clinical activities related to the oncology therapeutics HALAVEN® and LENVIMATM. Prior to that, Dr. Das was head of the neuro-oncology program at Cedars-Sinai Medical Center. Dr. Das is certified in neurology by the American Board of Psychiatry and Neurology and in the sub-specialty of neuro-oncology by the United Council for Neurologic Subspecialties and previously served as a clinical fellow in neuro-oncology at Massachusetts General Hospital. Dr. Das completed her residency in neurology at Cornell Medical Center and has held academic appointments at the University of California, Los Angeles; University of California, San Francisco; and National University of Singapore. Dr. Das obtained her medical degree and bachelor’s degree from Cornell University.